Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KYTX
KYVERNA THERAPEUTICS, INC.
NASDAQ
$8.25
▼ DOWN 1.20% (-0.10)

KEY STATISTICS

Market Cap$504.60 M
52w High$13.67
52w Low$3.72
Dividend Yield—
Frequency—
P/E-2.81
Volume499.07K
Shares Out.60.80M

COMPANY

LEADERSHIP

Warner Biddle
CHIEF EXECUTIVE
Warner Biddle

COMPENSATION 2026

Salary$625,000
Stock Awards$0
Incentive Plan Pay$468,750
All Other Comp.$177,426
Total$1,814,980

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 9, 2024
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
149

PRICE TARGET

Target High$25.00
Target Low$25.00
Target Median$25.00
Target Consensus$25.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

PRICE

$8.25 ▼ DOWN 1.20% (−$0.10)
$8.20$8.25$8.30$8.359:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM8.25

About Kyverna Therapeutics, Inc.

https://kyvernatx.com ↗

Kyverna Therapeutics is a clinical-stage biotech developing autologous and allogeneic CAR T-cell therapies for autoimmune diseases like lupus nephritis, multiple sclerosis, and inflammatory bowel disease.

INDUSTRY

Biotechnology

A PRODUCT KYVERNA THERAPEUTICS, INC. IS KNOWN FOR

mivocabtagene autoleucel (miv-cel)
mivocabtagene autoleucel (miv-cel)

Mivocabtagene autoleucel (KYV-101) is an investigational, fully human CD19 CAR T-cell therapy by Kyverna, in late-stage trials for autoimmune diseases like stiff person syndrome and myasthenia gravis, aiming for regulatory approval.

COMPETITORS

COMPETITOR
ATRA COMPARE
CABA COMPARE
CRBU COMPARE
CRSP COMPARE
NTLA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
70
LISTED HERE
14
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.4M
IWM
0.01% · 1.1M
FESM
0.06% · 471.7K
KOMP
0.08% · 258.9K
SURI
1.71% · 182.6K
SCHA
0.01% · 180.8K
AVSC
0.02% · 66.7K
XRS2.DE
0.01% · 37.4K
PRFZ
0.01% · 30.6K
GSSC
0.02% · 25.8K
RSSL
0.01% · 19.8K
DFAS
0.00% · 15.9K
BIB
0.02% · 2.2K
RESM
0.01% · 74

INSTITUTIONAL OWNERSHIP

SHARES OWNED
46.17%
HOLDERS
139
TOP 12 OF 139 · RANKED BY POSITION SIZE
Vida Ventures Advisors, LLC
4.5M sh · $27.14M
Gilead Sciences, Inc.
4.1M sh · $35.61M
Bain Capital Life Sciences Investors, LLC
3.4M sh · $20.21M
Northpond Ventures, LLC
3.3M sh · $15.92M
Deerfield Management Company, L.P. (Series C)
2.0M sh · $17.26M
Aigh Capital Management LLC
2.0M sh · $17.26M
Vanguard Group Inc
1.8M sh · $16.74M
Price T Rowe Associates Inc /Md/
1.8M sh · $16.57M
Adage Capital Partners Gp, L.L.C.
1.7M sh · $15.67M
Blackrock Inc.
1.5M sh · $10.9M
Balyasny Asset Management L.P.
1.1M sh · $9.71M
Millennium Management LLC
1.0M sh · $8.68M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Aktar Mert
Purchase · 20.6K shares
2026-05-27
★
DIRECTOR
Aktar Mert
Purchase · 5.1K shares
2026-05-27
★
DIRECTOR
CLARK IAN T
Purchase · 5.1K shares
2026-05-27
★
DIRECTOR
CLARK IAN T
Purchase · 20.6K shares
2026-05-27

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 3
BUY 1
4 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY JP Morgan OVERWEIGHT Wells Fargo OVERWEIGHT Morgan Stanley OVERWEIGHT

SECTORS PEERS

PEERPRICE
SLN$14.63COMPARE
ALLO$1.98COMPARE
CTNM$16.95COMPARE
CABA$3.46COMPARE
CAPR$9.47COMPARE
EDIT$3.18COMPARE
AVIR$5.87COMPARE
LXEO$4.97COMPARE